methoxsalen has been researched along with Cutaneous T-Cell Lymphoma in 32 studies
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.
methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Fourteen patients (all male) aged 38 to 72 years with CTCL of the mycosis fungoides type, stage IIa/IIb, and a 72-year-old male patient with a Ki-1 lymphoma were treated twice a month for 6 months with extracorporeal photochemotherapy using oral 8-methoxypsoralen as photosensitizer in combination with interferon alfa-2a subcutaneously 3 times a week in the maximal tolerable dosage (ie, up to 18 x 10(6) U)." | 2.70 | Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial. ( Hipler, UC; Knopf, B; Koch, HJ; Liebold, K; Looks, A; Meyer, J; Wollina, U, 2001) |
| " Safety was assessed using reports of adverse device effects (ADEs) and unanticipated ADEs (UADEs), device malfunctions and defects, vital signs, laboratory parameters and physical examinations." | 1.35 | Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma. ( Bisaccia, E; Geskin, L; Vonderheid, EC, 2009) |
| "Hypericin is a photodynamic compound activated by either visible (400-700 nm) or UVA (320-400 nm) light, and has been shown to inhibit the growth of a variety of neoplastic cell types." | 1.30 | Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders. ( Fox, FE; Niu, Z; Rook, AH; Tobia, A, 1998) |
| " In serum, peak 8-MOP concentrations were reached < or =40 min following ingestion; the half-life of 8-MOP in the serum was 50+/-14 min (n=7)." | 1.30 | Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis. ( Nestle, FO; Panizzon, R; Shephard, SE, 1999) |
| "The number of chromosomal aberrations and SCE were increased upon treatment, but only transiently, returning to basal levels between consecutive treatments." | 1.28 | Cytogenetic effects during extracorporeal photopheresis treatment of two patients with cutaneous T-cell lymphoma. ( Gebauer, HJ; Küster, W; Meschig, R; Peterseim, UM; Plewig, G, 1991) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 19 (59.38) | 18.2507 |
| 2000's | 5 (15.63) | 29.6817 |
| 2010's | 7 (21.88) | 24.3611 |
| 2020's | 1 (3.13) | 2.80 |
| Authors | Studies |
|---|---|
| Nakahashi, K | 1 |
| Nihira, K | 1 |
| Suzuki, M | 1 |
| Ishii, T | 1 |
| Masuda, K | 1 |
| Mori, K | 1 |
| Szczepiorkowski, ZM | 1 |
| Burnett, CA | 1 |
| Dumont, LJ | 1 |
| Abhyankar, SH | 1 |
| Holien, T | 1 |
| Gederaas, OA | 1 |
| Darvekar, SR | 1 |
| Christensen, E | 1 |
| Peng, Q | 1 |
| Trautinger, F | 2 |
| Tatsuno, K | 1 |
| Yamazaki, T | 1 |
| Hanlon, D | 1 |
| Han, P | 1 |
| Robinson, E | 1 |
| Sobolev, O | 1 |
| Yurter, A | 1 |
| Rivera-Molina, F | 1 |
| Arshad, N | 1 |
| Edelson, RL | 3 |
| Galluzzi, L | 1 |
| Taverna, F | 1 |
| Coluccia, P | 1 |
| Arienti, F | 1 |
| Birolini, A | 1 |
| Terranova, L | 1 |
| Mazzocchi, A | 1 |
| Rini, F | 1 |
| Mariani, L | 1 |
| Melani, C | 1 |
| Ravagnani, F | 1 |
| Bisaccia, E | 2 |
| Vonderheid, EC | 1 |
| Geskin, L | 1 |
| Kofoed, K | 1 |
| Schiødt, I | 1 |
| Gniadecki, R | 1 |
| Just, U | 1 |
| Knobler, R | 2 |
| Crovetti, G | 1 |
| Carabelli, A | 1 |
| Berti, E | 1 |
| Guizzardi, M | 1 |
| Fossati, S | 1 |
| De Filippo, C | 1 |
| Bertani, E | 1 |
| Umeh, OC | 1 |
| Kubak, BM | 1 |
| Pegues, DA | 1 |
| Leibowitz, MR | 1 |
| Froch, L | 1 |
| Schreiner, T | 1 |
| Gaczkowski, A | 1 |
| Scharffetter-Kochanek, K | 1 |
| Borberg, H | 1 |
| Bunn, PA | 1 |
| Lim, HW | 1 |
| Wolf, P | 1 |
| Müllegger, R | 1 |
| Cerroni, L | 1 |
| Aigner, R | 1 |
| Fueger, G | 1 |
| Höfler, G | 1 |
| Derbaschnig, J | 1 |
| Kerl, H | 1 |
| Duvic, M | 1 |
| Hester, JP | 1 |
| Lemak, NA | 1 |
| Gasparro, FP | 3 |
| Felli, A | 1 |
| Schmitt, IM | 1 |
| Zic, JA | 2 |
| Stricklin, GP | 3 |
| Greer, JP | 1 |
| Kinney, MC | 1 |
| Shyr, Y | 1 |
| Wilson, DC | 1 |
| King, LE | 3 |
| Fox, FE | 1 |
| Niu, Z | 1 |
| Tobia, A | 1 |
| Rook, AH | 1 |
| Miller, JL | 1 |
| Shephard, SE | 2 |
| Nestle, FO | 1 |
| Panizzon, R | 1 |
| Panizzon, RG | 1 |
| Wollina, U | 1 |
| Looks, A | 1 |
| Meyer, J | 1 |
| Knopf, B | 1 |
| Koch, HJ | 1 |
| Liebold, K | 1 |
| Hipler, UC | 1 |
| Heald, P | 1 |
| Rook, A | 1 |
| Perez, M | 1 |
| Wintroub, B | 1 |
| Jegasothy, B | 1 |
| Gasparro, F | 1 |
| Berger, C | 2 |
| Edelson, R | 1 |
| Zic, J | 1 |
| Arzubiaga, C | 1 |
| Salhany, KE | 1 |
| Parker, RA | 1 |
| Wilson, D | 1 |
| Greer, J | 1 |
| Strauss, RG | 1 |
| Malane, MS | 1 |
| Peterseim, UM | 1 |
| Küster, W | 1 |
| Gebauer, HJ | 1 |
| Meschig, R | 1 |
| Plewig, G | 1 |
| Marks, DI | 1 |
| Rockman, SP | 1 |
| Oziemski, MA | 1 |
| Fox, RM | 1 |
| Armus, S | 1 |
| Keyes, B | 1 |
| Cahill, C | 1 |
| Crater, D | 1 |
| Scarborough, D | 1 |
| Klainer, A | 1 |
| Heald, PW | 1 |
| Perez, MI | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Use of Extracorporeal Photopheresis as Immunomodulatory Therapy of Subclinical Antibody-mediated Rejection After Lung Transplantation: a Prospective RCT[NCT06112951] | 80 participants (Anticipated) | Interventional | 2023-11-01 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
9 reviews available for methoxsalen and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Phototherapy of cutaneous T-cell lymphomas.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Lymphomatoid Papulosis; Methoxsalen; Mycosis Fungoides; Photose | 2018 |
[Documented effect of extra corporeal photopheresis on T-cell mediated diseases].
Topics: Evidence-Based Medicine; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Ph | 2011 |
Photopheresis (extracorporeal photochemotherapy).
Topics: Graft Rejection; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Photophere | 2013 |
Photopheresis for the treatment of cutaneous T-cell lymphoma.
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Photopheresis; Skin Neoplasms | 1995 |
Psoralen photobiology: the relationship between DNA damage, chromatin structure, transcription, and immunogenic effects.
Topics: Animals; Base Composition; Base Sequence; Chromatin; DNA; DNA Damage; Furocoumarins; Humans; Lymphom | 1997 |
The North American experience with photopheresis.
Topics: Arthritis, Rheumatoid; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Nort | 1999 |
Current status of hemapheresis in the United States.
Topics: Blood Banks; Blood Component Removal; Blood Transfusion, Autologous; Data Collection; Hematopoietic | 1991 |
T cell molecular targets for psoralens.
Topics: Animals; DNA; Humans; Lipid Metabolism; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Proteins; PUVA The | 1991 |
Photopheresis: present and future aspects.
Topics: Animals; Humans; Immune System Diseases; Immunotherapy; Lymphocyte Depletion; Lymphoma, T-Cell, Cuta | 1991 |
2 trials available for methoxsalen and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
Apheresis buffy coat collection without photoactivation has no effect on apoptosis, cell proliferation, and total viability of mononuclear cells collected using photopheresis systems.
Topics: Adult; Annexin A5; Apoptosis; Blood Buffy Coat; Blood Component Removal; Cell Proliferation; Cells, | 2018 |
Treatment of stage II cutaneous T-cell lymphoma with interferon alfa-2a and extracorporeal photochemotherapy: a prospective controlled trial.
Topics: Administration, Oral; Adult; Aged; Antineoplastic Agents; Humans; Injections, Subcutaneous; Interfer | 2001 |
21 other studies available for methoxsalen and Cutaneous T-Cell Lymphoma
| Article | Year |
|---|---|
A novel mouse model of cutaneous T-cell lymphoma revealed the combined effect of mogamulizumab with psoralen and ultraviolet a therapy.
Topics: Animals; Ficusin; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Mice; Mycosis Fungoides; PUVA Therapy; S | 2022 |
Comparison between 8-methoxypsoralen and 5-aminolevulinic acid in killing T cells of photopheresis patients ex vivo.
Topics: Aminolevulinic Acid; Cell Culture Techniques; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutan | 2018 |
Extracorporeal photochemotherapy induces bona fide immunogenic cell death.
Topics: Adenosine Triphosphate; Animals; Antigens, Neoplasm; Apoptosis; CD8-Positive T-Lymphocytes; Cell Dif | 2019 |
Biological quality control for extracorporeal photochemotherapy: Assessing mononuclear cell apoptosis levels in ECP bags of chronic GvHD patients.
Topics: Adult; Aged; Apoptosis; Blood Component Removal; Cell Proliferation; Cell Separation; Female; Flow C | 2015 |
Safety of a new, single, integrated, closed photopheresis system in patients with cutaneous T-cell lymphoma.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Drug Administration Schedule; Equ | 2009 |
Photopheresis in cutaneous T-cell lymphoma: five-year experience.
Topics: Adult; Aged; Antineoplastic Agents; Female; Humans; Interferon-alpha; Lymphoma, T-Cell, Cutaneous; M | 2000 |
Corynebacterium jeikeium sepsis after 8-methoxypsolaren photopheresis for cutaneous T-cell lymphoma.
Topics: Aged; Bacteremia; Corynebacterium; Corynebacterium Infections; Follow-Up Studies; Humans; Immunocomp | 2004 |
Small-scale extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma: a report of 3 cases.
Topics: Aged; Aged, 80 and over; Female; Humans; Lymphoma, T-Cell, Cutaneous; Male; Methoxsalen; Middle Aged | 2005 |
Cutaneous T cell lymphomas.
Topics: Administration, Topical; Humans; Lymphoma, T-Cell, Cutaneous; Mechlorethamine; Methoxsalen; Randomiz | 1994 |
Photoaccentuated erythroderma associated with CD4+ T lymphocytopenia: successful treatment with 5-methoxypsoralen and UVA, interferon alfa-2b, and extracorporeal photopheresis.
Topics: 5-Methoxypsoralen; Dermatitis, Exfoliative; HIV Seronegativity; Humans; Interferon alpha-2; Interfer | 1996 |
Photopheresis therapy for cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Dermatitis, Exfoliative; Female; Follow-Up Studies; Forecasting; Hum | 1996 |
Long-term follow-up of patients with cutaneous T-cell lymphoma treated with extracorporeal photochemotherapy.
Topics: Adult; Aged; Aged, 80 and over; Female; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Male | 1996 |
Photoactivated hypericin is an anti-proliferative agent that induces a high rate of apoptotic death of normal, transformed, and malignant T lymphocytes: implications for the treatment of cutaneous lymphoproliferative and inflammatory disorders.
Topics: Anthracenes; Antineoplastic Agents; Apoptosis; Cells, Cultured; Humans; Keratitis; Lymphocyte Activa | 1998 |
Pharmacokinetics of 8-methoxypsoralen during extracorporeal photopheresis.
Topics: Adult; Aged; Biological Availability; Chromatography, High Pressure Liquid; Dose-Response Relationsh | 1999 |
Carcinogenic risk of bath PUVA in comparison to oral PUVA therapy.
Topics: 5-Methoxypsoralen; Administration, Oral; Administration, Topical; Baths; DNA Adducts; Female; Humans | 1999 |
Treatment of erythrodermic cutaneous T-cell lymphoma with extracorporeal photochemotherapy.
Topics: CD4-CD8 Ratio; Dermatitis, Exfoliative; Follow-Up Studies; Humans; Lymphoma, T-Cell, Cutaneous; Meth | 1992 |
Extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Combined Modality Therapy; Extracorporeal Circulation; Female; Human | 1992 |
Cytogenetic effects during extracorporeal photopheresis treatment of two patients with cutaneous T-cell lymphoma.
Topics: Administration, Oral; Aged; Chromosome Aberrations; Female; Humans; Lymphocytes; Lymphoma, T-Cell, C | 1991 |
Mechanisms of lymphocytotoxicity induced by extracorporeal photochemotherapy for cutaneous T cell lymphoma.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Deoxyadenosines; DNA; DNA Damage; Humans; In Vitro Tech | 1990 |
Photopheresis for the treatment of cutaneous T cell lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Dermatitis, Exfoliative; Female; Humans; Leukapheresis; Lymphoma, T- | 1990 |
Dosage guidelines: extracorporeal photochemotherapy (photopheresis)
Topics: Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Photochemotherapy; Skin Neoplasms | 1990 |